Lack of hippocampal CB1 receptor desensitization by Δ9-tetrahydrocannabinol in aged mice and by low doses of JZL 184
Abstract
Activation of cannabinoid CB1 receptors may offer new therapeutic strategies, but the efficiency of CB1 receptor agonists may be impaired by tolerance development upon prolonged administration. We compared the influence of repeated administration of Δ(9)-tetrahydrocannabinol (THC) 10 mg/kg on the motility and on basal and CB1 receptor-stimulated (35)S-GTPγS binding of adolescent and aged mice. Moreover, we determined the influence of JZL 184 (which inhibits the 2-arachidonoylglycerol, 2-AG, degrading enzyme monoacylglycerol lipase, MAGL) on (35)S-GTPγS binding and 2-AG levels of young adult mice. Mouse motility was tested in the open field. (35)S-GTPγS binding was studied in hippocampal membranes. THC and CP 55,940 were used as cannabinoid agonists in the behavioural and biochemical studies, respectively. 2-AG levels were quantified by liquid chromatography-multiple reaction monitoring. The THC (10 mg/kg)-induced hypomotility was stronger in untreated than in THC-pretreated adolescent mice but similar in both treatment groups of aged mice. Basal and stimulated (35)S-GTPγS binding was decreased in membranes from THC-pretreated adolescent but not affected in membranes from aged mice. Treatment of young adult mice with JZL 184 (4, 10 and 40 mg/kg) for 14 days did not affect basal binding. Stimulated binding tended to be decreased by 25 % only in mice treated with JZL 184 (40 mg/kg). Hippocampal 2-AG level was increased by JZL 184 at 40 and 10 but not affected at 4 mg/kg. In conclusion, CB1 receptor tolerance does not occur in aged mice pretreated with THC and in young adult mice treated with a low dose of the MAGL inhibitor JZL 184.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CB1R desensitization is not seen at lower doses of MAGL inhibitors.
“Although CB1R desensitization is not seen at lower doses of MAGL inhibitors (Feliszek et al., 2016; Kinsey et al., 2013)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Feliszek et al., 2016
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · see citing works
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819 · see citing works
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,610 · see citing works
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,514 · see citing works
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · see citing works
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,065 · see citing works
Self-citationSelective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A., Selley, D. E., Parsons, L. H., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 938 · see citing works
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 663 · see citing works
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2616 · Cited by 641 · see citing works
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 555 · see citing works
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Marzo, V. D., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 537 · see citing works
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444 · see citing works
Endocannabinoid signalling and the deteriorating brain
Marzo, V. D., Stella, N., & Zimmer, A. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3876 · Cited by 381 · see citing works
Self-citationThe therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 344 · see citing works
Wang, L., Liu, J., Harvey-White, J. D., Zimmer, A., & Kunos, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336351100 · Cited by 340 · see citing works
Self-citationAttenuation of Allergic Contact Dermatitis Through the Endocannabinoid System
Karsak, M., Gaffal, E., Date, R., Wang‐Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B. F., et al. (2007) · Science · doi:10.1126/science.1142265 · Cited by 338 · see citing works
Self-citationChemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327 · see citing works
Sim, L. J., Hampson, R. E., Deadwyler, S. A., & Childers, S. R. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08057.1996 · Cited by 311 · see citing works
Regulation of Cannabinoid CB1 Receptors in the Central Nervous System by Chronic Cannabinoids
Sim‐Selley, L. J. (2003) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v15.i2.10 · Cited by 271 · see citing works
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
González, S. R., Cebeira, M., & Fernández‐Ruíz, J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.028 · Cited by 258 · see citing works
Effects of Cannabinoids on Neurotransmission
Szabó, B., & Schlicker, E. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_11 · Cited by 256 · see citing works
Self-citationThe endocannabinoid system in anxiety, fear memory and habituation
Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408958 · Cited by 236 · see citing works
Self-citationKinsey, S. G., Wise, L. E., Ramesh, D., Abdullah, R., Selley, D. E., Cravatt, B. F., & Lichtman, A. H. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201426 · Cited by 169 · see citing works
Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors
Bilkei‐Gorzó, A., Rácz, I., Valverde, O., Otto, M., Michel, K., Sarstre, M., & Zimmer, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504640102 · Cited by 166 · see citing works
Self-citationQuantification of brain endocannabinoid levels: methods, interpretations and pitfalls
Buczynski, M. W., & Parsons, L. H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00787.x · Cited by 160 · see citing works
The endocannabinoid system in normal and pathological brain ageing
Bilkei‐Gorzó, A. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0388 · Cited by 157 · see citing works
Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging
Albayram, Ö., Alferink, J., Pitsch, J., Piyanova, A., Neitzert, K., Poppensieker, K., Mauer, D., Michel, K., Legler, A., Becker, A. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016442108 · Cited by 129 · see citing works
Self-citationMore surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128 · see citing works
Ghosh, S., Wise, L. E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B. F., & Lichtman, A. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.06.020 · Cited by 127 · see citing works
Signaling pathways involved in the development of cannabinoid tolerance
Martin, B. R., Sim‐Selley, L. J., & Selley, D. E. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.005 · Cited by 115 · see citing works
Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex
Long, L. E., Lind, J., Webster, M. J., & Weickert, C. S. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-87 · Cited by 115 · see citing works
Sim‐Selley, L. J., Schechter, N. S., Rorrer, W. K., Dalton, G. D., Hernandez, J., Martin, B. R., & Selley, D. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019612 · Cited by 115 · see citing works
Nguyen, P., Schmid, C. L., Raehal, K. M., Selley, D. E., Bohn, L., & Sim‐Selley, L. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.027 · Cited by 113 · see citing works
Strange, P. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00963.x · Cited by 110 · see citing works
Wu, D., Yang, L., Goschke, A., Stumm, R. K., Brandenburg, L., Liang, Y.-J., Höllt, V., & Koch, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05063.x · Cited by 107 · see citing works
The role of endocannabinoids in pain modulation
Zogopoulos, P., Vasileiou, I., Patsouris, E., & Theocharis, S. E. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12008 · Cited by 106 · see citing works
Age-Dependent Opioid Escalation in Chronic Pain Patients
Buntin-Mushock, C., Phillip, L., Moriyama, K., & Pierce, P. A. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000152191.29311.9b · Cited by 104 · see citing works
Endocannabinoids and Retrograde Modulation of Synaptic Transmission
Ohno‐Shosaku, T., Tanimura, A., Hashimotodani, Y., & Kano, M. (2011) · The Neuroscientist · doi:10.1177/1073858410397377 · Cited by 104 · see citing works
Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice
Bass, C. E., & Martin, B. R. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00150-7 · Cited by 101 · see citing works
Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids
Puighermanal, E., Busquets-García, A., Maldonado, R. J., & Ozaita, A. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0384 · Cited by 101 · see citing works
Age-related changes in the endocannabinoid system in the mouse hippocampus
Piyanova, A., Lomazzo, E., Bîndilă, L., Lerner, R., Albayram, Ö., Ruhl, T., Lutz, B., Zimmer, A., & Bilkei‐Gorzó, A. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.08.005 · Cited by 99 · see citing works
Self-citationDissociation of the Pharmacological Effects of THC by mTOR Blockade
Puighermanal, E., Busquets-García, A., Gomis‐González, M., Marsicano, G., Maldonado, R. J., & Ozaita, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.31 · Cited by 91 · see citing works
McKinney, D. L., Cassidy, M. P., Collier, L., Martin, B. R., Wiley, J. L., Selley, D. E., & Sim‐Selley, L. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130328 · Cited by 89 · see citing works
Temporal changes in N‐acylethanolamine content and metabolism throughout the peri‐adolescent period
Lee, T. T. ‐., Hill, M. N., Hillard, C. J., & Gorzalka, B. B. (2012) · Synapse · doi:10.1002/syn.21609 · Cited by 68 · see citing works
Bilkei‐Gorzó, A., Drews, E., Albayram, Ö., Piyanova, A., Gaffal, E., Tueting, T., Michel, K., Mauer, D., Maier, W., & Zimmer, A. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.009 · Cited by 65 · see citing works
Self-citationVlachou, S., & Panagis, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990433 · Cited by 60 · see citing works
Brain regional differences in CB1 receptor adaptation and regulation of transcription
Lazenka, M. F., Selley, D. E., & Sim‐Selley, L. J. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.08.023 · Cited by 55 · see citing works
Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction
Wenzel, D., Matthey, M., Bîndilă, L., Lerner, R., Lutz, B., Zimmer, A., & Fleischmann, B. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308130110 · Cited by 54 · see citing works
Self-citationMato, S., & Pazos, Á. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.004 · Cited by 53 · see citing works
Age-Dependent Morphine Tolerance Development in the Rat
Wang, Y., Mitchell, J., Moriyama, K., Kim, K.-J., Sharma, M. L., Xie, G.-X., & Pierce, P. A. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000152192.23851.40 · Cited by 52 · see citing works
Tai, S., Hyatt, W. S., Gu, C., Franks, L. N., Vasiljevik, T., Brents, L. K., Prather, P. L., & Fantegrossi, W. E. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.006 · Cited by 49 · see citing works
González‐Maeso, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00342-6 · Cited by 44 · see citing works
Agonist-stimulated [35S]GTPγS binding in brain
Moore, R. J., Xiao, R., Sim‐Selley, L. J., & Childers, S. R. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00112-4 · Cited by 41 · see citing works
Irie, T., Kikura‐Hanajiri, R., Usami, M., Uchiyama, N., Goda, Y., & Sekino, Y. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.025 · Cited by 36 · see citing works
Scherma, M., Fattore, L., Castelli, M. P., Fratta, W., & Fadda, P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990429 · Cited by 36 · see citing works
Moore, N. L. T., Greenleaf, A. L. R., Acheson, S. K., Wilson, W. A., Swartzwelder, H. S., & Kuhn, C. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169359 · Cited by 35 · see citing works
Loss of CB1 receptors leads to differential age-related changes in reward-driven learning and memory
Albayram, Ö., Bilkei‐Gorzó, A., & Zimmer, A. (2012) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2012.00034 · Cited by 34 · see citing works
Self-citationYi, J., Zheng, J., Zhang, W., Wang, S., Yang, Z., & Ke-feng, D. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-38 · Cited by 32 · see citing works
Piyanova, A., Albayram, Ö., Rossi, C. A., Farwanah, H., Michel, K., Nicotera, P., Sandhoff, K., & Bilkei‐Gorzó, A. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.001 · Cited by 31 · see citing works
Molecular and Cellular Mechanisms of the Age-Dependency of Opioid Analgesia and Tolerance
Zhao, J., Xin, X., Xie, G.-X., Pierce, P. A., & Huang, Y. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-38 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance
Ramaekers, J. G., Mason, N. L., & Theunissen, E. L. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.006 · Cited by 85 · see citing works
Cannabinoid Modulation of the Stressed Hippocampus
Scarante, F. F., Vila-Verde, C., Lopes, V. D., Ferreira‐Junior, N. C., Guimarães, F. S., & Campos, A. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00411 · Cited by 64 · see citing works
Alteba, S., Zer‐Aviv, T. M., Tenenhaus, A., David, G. B., Adelman, J. W., Hillard, C. J., Doron, R., & Akirav, I. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.005 · Cited by 37 · see citing works
Nidadavolu, P., Bilkei‐Gorzó, A., Krämer, M., Schürmann, B., Palmisano, M., Beins, E. C., Madea, B., & Zimmer, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718850 · Cited by 32 · see citing works
Self-citationNidadavolu, P., Bilkei‐Gorzó, A., Effah, F., Leidmaa, E., Schürmann, B., Berger, M., Bîndilă, L., Schmid, M. C., Lutz, B., Zimmer, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810254 · Cited by 32 · see citing works
Self-citationTargeting 2‐arachidonoylglycerol signalling in the neurobiology and treatment of depression
Silveira, K. M., Wegener, G., & Joca, S. R. L. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13595 · Cited by 30 · see citing works
Leishman, E., Mackie, K., & Bradshaw, H. B. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00142 · Cited by 28 · see citing works
Palmisano, M., Gargano, A., Olabiyi, B. F., Lutz, B., & Bilkei‐Gorzó, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010026 · Cited by 25 · see citing works
Self-citationKomorowska‐Müller, J. A., Gellner, A., Ravichandran, K. A., Bilkei‐Gorzó, A., Zimmer, A., & Stein, V. (2023) · Scientific Reports · doi:10.1038/s41598-022-27146-2 · Cited by 20 · see citing works
Self-citationCannabinoid 1 receptor signaling on GABAergic neurons influences astrocytes in the ageing brain
Bilkei‐Gorzó, A., Albayram, Ö., Ativie, F., Chasan, S., Zimmer, T. S., Bach, K., & Zimmer, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202566 · Cited by 20 · see citing works
Self-citationSagar, K. A., & Gruber, S. A. (2025) · CNS Drugs · doi:10.1007/s40263-024-01148-2 · Cited by 18 · see citing works
Radhakrishnan, R., Worhunsky, P. D., Zheng, M., Najafzadeh, S., Gallezot, J., Planeta, B. M., Henry, S. E., Nabulsi, N., Ranganathan, M., Skosnik, P. D., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119674 · Cited by 18 · see citing works
Maguire, G., Eubanks, C., & Ayoub, G. (2022) · Neuronal Signaling · doi:10.1042/ns20210038 · Cited by 12 · see citing works
Papadogkonaki, S., Spyridakos, D., Lapokonstantaki, E., Chaniotakis, N. A., Makriyannis, A., Malamas, M. S., & Thermos, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115689 · Cited by 7 · see citing works
Augmentation of Endogenous 2-Arachidonoylglycerol Mitigates Autistic Behaviors of BTBR Mice
Zou, M., Zhang, Y., Du, C., Yang, B., Guo, P., Liang, H., Zhang, Y., Tian, W., Yang, L., Liu, D., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04606-6 · Cited by 6 · see citing works
Asher, M. J., McMullan, H. M., Dong, A., Li, Y., & Thayer, S. A. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.122.000555 · Cited by 6 · see citing works
Sepers, M. D., Woodard, C. L., Ramandi, D., Vecchiarelli, H. A., Hill, M. N., & Raymond, L. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614804 · Cited by 2 · see citing works
Ravula, H., Yadav-Samudrala, B. J., Sawaqed, L. E., Arciniega, C., Hu, W., Jiang, W., & Fitting, S. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106476 · Cited by 1 · see citing works
Wu, Y., Fang, F., Fan, X., & Nie, H. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2024.0027 · Cited by 1 · see citing works
Sepers, M. D., Woodard, C. L., Ramandi, D., Vecchiarelli, H. A., Hill, M. N., & Raymond, L. A. (2025) · Journal of Huntington s Disease · doi:10.1177/18796397251337021 · Cited by 1 · see citing works
Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice
Keller, C., Rading, S., Candur, B., Bîndilă, L., Loers, G., & Karsak, M. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102571
- Authors
- Feliszek, M., Bindila, L., Lutz, B., Zimmer, A., Bilkei-Gorzo, A., & Schlicker, E.
- Affiliations
- University of Bonn (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Schlicker, Eberhard
- Venue
- Naunyn-Schmiedeberg s Archives of Pharmacology
- Published
- 2016-03-17
- Volume
- 389
- Issue
- 6
- Pages
- 603-612
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W2461742539
- Cited by
- 22
- References
- 60
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 2
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Naunyn-Schmiedeberg s Archives of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Agence Nationale pour la Gestion des Déchets Radioactifs
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- cannabinoid tolerance, delta-9-tetrahydrocannabinol, monoacylglycerol lipase inhibition, 2-arachidonoylglycerol, hippocampus, aged mice, locomotor activity, GTPgammaS binding, CP55,940, cannabinoid receptor agonists
- MeSH terms
- Age Factors, Animals, Arachidonic Acids, Behavior, Animal, Dose-Response Relationship, Drug, Drug Tolerance, Enzyme Inhibitors, Genotype, Glycerides, Hippocampus, Male, Mice, Inbred C57BL, Monoacylglycerol Lipases, Motor Activity, Phenotype, Piperidines, Dronabinol, Guanosine 5'-O-(3-Thiotriphosphate), Mice, Knockout, Receptor, Cannabinoid, CB1, Benzodioxoles, Cannabinoid Receptor Agonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
